Pitt Street Research’s highlights (excerpts):
https://static1.squarespace.com/static/5af533a312b13fb602fe7d7b/t/686cbe7b41a93627bbb447a9/1751957122744/Prescient%2BTherapeutics%2Bresearch%2Breinitiation%2Breport%2B09%2B07%2B2025.pdf%26sa=D%26source=docs%26ust=1753860831791383%26usg=AOvVaw3C2O3zkfeeFjSKzO_T_owX?utm_campaign=12916036-%5BLI%5D%20PTX%20MAY%202025&utm_medium=email&_hsenc=p2ANqtz-8FaeZexfGbynhz8idxrP5ZuTaNdcL9HNw7ud2mxrSPshmfJlkcMxwo-0CygJpjLsdQbzuKvITzyjmZUpzNhBeJtxH8pQ&_hsmi=11105965&utm_content=11105965&utm_source=hs_email
- “PTX-100 has shown strong potential in Phase 1, not just trouncing existing standards of care, but working in patients where previous treatments have failed.”
- How PTX-100 “with a price of US$450,000 (using Acrotech Biopharma’s Folotyn as a guide)...could make US$2.5bn in sales”
- “PTX-100 could be applicable to any cancer that could be defeated with an RAS therapy. This could be 22% of all cancers.”
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
4.0¢ |
Change
-0.001(2.44%) |
Mkt cap ! $42.06M | |||
| Open | High | Low | Value | Volume |
| 4.1¢ | 4.1¢ | 4.0¢ | $9.253K | 226.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 1533201 | 4.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.1¢ | 250951 | 2 |
View Market Depth
| Last trade - 16.10pm 05/09/2025 (20 minute delay) ? |
| PTX (ASX) Chart |